Seek Returns

BIO.B vs. GMAB: Bio-Rad Laboratories vs. Genmab Stock Comparison

How do Bio-Rad Laboratories (BIO.B) and Genmab (GMAB) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bio-Rad Laboratories (BIO.B) and Genmab (GMAB) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO.B is classified in Life Sciences Tools & Services while GMAB is classified in Biotechnology.

Bio-Rad Laboratories (BIO.B) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for Bio-Rad Laboratories (BIO.B) and Genmab (GMAB)
Profile ItemBIO.BGMAB
NameBio-Rad Laboratories, Inc. Class B Common StockGenmab A/S American Depositary Shares
Country/RegionUnited StatesDenmark
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization10.49 billion USD31.67 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateSeptember 21, 1999June 1, 2009
Security TypeCommon StockADR

Price Performance

Cumulative Growth

BIO.B
GMAB
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Genmab (GMAB), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Bio-Rad Laboratories (BIO.B) and Genmab (GMAB). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Bio-Rad Laboratories (BIO.B) and Genmab (GMAB). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bio-Rad Laboratories (BIO.B) and Genmab (GMAB)
MetricBIO.BGMAB
Total Return (1Y)27.69%69.87%
Total Return (3Y, Annualized)9.13%16.91%
Total Return (5Y, Annualized)-12.33%3.39%

Risk Profile

Drawdown History

BIO.B
GMAB
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Genmab (GMAB), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Bio-Rad Laboratories (BIO.B) and Genmab (GMAB). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Genmab (GMAB) trades around 4.20M shares per day on average, while Bio-Rad Laboratories (BIO.B) sees only 11 — a volume gap that can matter for position sizing, exit liquidity, and order execution.

Risk profile metrics for Bio-Rad Laboratories (BIO.B) and Genmab (GMAB)
MetricBIO.BGMAB
Volatility (1Y, Annualized)30.96%45.85%
Beta (5Y)1.000.72
Max Drawdown (5Y)-70.74%-61.79%
Avg. Volume (3M)114.20M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BIO.B and GMAB are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bio-Rad Laboratories (BIO.B) and Genmab (GMAB)
MetricBIO.BGMAB
Sharpe Ratio (1Y)0.741.42
Sortino Ratio (1Y)1.102.81

Profitability

ROE (TTM)

Both Bio-Rad Laboratories (BIO.B) at 14.27% and Genmab (GMAB) at 12.07% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max
109.18%
BIO.B
14.27%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.07%

Max
109.18%
GMAB
12.07%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Genmab (GMAB): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Bio-Rad Laboratories (BIO.B) at 39.45% keeps the most of each sales dollar — above its industry’s net margin range — and Genmab (GMAB) at 16.97% also retains a top-quartile share.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO.B
39.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

16.97%

Max
18.05%
GMAB
16.97%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Genmab (GMAB): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Genmab (GMAB) at 30.63% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO.B) at 9.46%, which runs around its industry’s norm.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.46%

Max
83.12%
Q3
14.77%
BIO.B
9.46%
Median
0.00%
Q1
-78.82%
Min
-207.40%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.63%

Max
83.12%
GMAB
30.63%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Genmab (GMAB): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bio-Rad Laboratories (BIO.B) and Genmab (GMAB)
MetricBIO.BGMAB
ROE (TTM)14.27%12.07%
ROA (TTM)1.50%8.24%
Net Margin (TTM)39.45%16.97%
Operating Margin (TTM)9.46%30.63%
Gross Margin (TTM)52.19%92.67%

Growth

Revenue Growth

Both Bio-Rad Laboratories (BIO.B) at 0.65% and Genmab (GMAB) at 19.19% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Genmab (GMAB): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Genmab (GMAB) reports EPS growth of -9.23%, ranked against its industry; Bio-Rad Laboratories (BIO.B) has no EPS growth figure this period.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Genmab (GMAB): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Bio-Rad Laboratories (BIO.B) and Genmab (GMAB)
MetricBIO.BGMAB
Revenue Growth (YoY)0.65%19.19%
Revenue Growth (3Y CAGR)-2.68%21.23%
EPS Growth (YoY)---9.23%
EPS Growth (3Y CAGR)--8.48%

Financial Strength

Current Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 3.18 keeps current ratio within its industry’s typical mid-range, while Genmab (GMAB) at 2.45 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GMAB.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max
25.13
Q3
12.13
Median
5.52
BIO.B
3.18
Q1
2.47
Min
0.10

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.45

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GMAB
2.45
Min
0.10
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Genmab (GMAB): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Bio-Rad Laboratories (BIO.B) at 0.18 carries an industry-typical debt-to-equity mix, while Genmab (GMAB) at 0.82 uses more debt funding than most peers.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max
1.42
Q3
0.65
BIO.B
0.18
Median
0.15
Q1
0.02
Min
0.00

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.82

Max
1.42
GMAB
0.82
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Genmab (GMAB): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Bio-Rad Laboratories (BIO.B) and Genmab (GMAB)
MetricBIO.BGMAB
Current Ratio (MRQ)3.182.45
Debt / Equity (MRQ)0.180.82
Net Debt / EBITDA-0.732.45

Dividends

Dividend Yield (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor Genmab (GMAB) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Genmab (GMAB): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Bio-Rad Laboratories (BIO.B) nor Genmab (GMAB) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

GMAB
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Genmab (GMAB): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bio-Rad Laboratories (BIO.B) and Genmab (GMAB)
MetricBIO.BGMAB
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO.B) at 10.36 sits in the cheaper P/E ratio quartile, while Genmab (GMAB) at 43.91 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.36

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
BIO.B
10.36
Min
0.07

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.91

Max
85.34
GMAB
43.91
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Genmab (GMAB): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Bio-Rad Laboratories (BIO.B) at 4.05 and Genmab (GMAB) at 7.37 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.05

Max
58.18
Q3
25.77
Median
7.30
BIO.B
4.05
Q1
3.01
Min
0.01

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.37

Max
58.18
Q3
25.77
GMAB
7.37
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Genmab (GMAB): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 1.38 sits in the lower P/B ratio quartile against book while Genmab (GMAB) at 5.13 is valued near its industry’s middle — BIO.B is cheaper on assets, though weigh it against ROE and asset quality.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BIO.B
1.38
Min
-5.59

GMAB

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.13

Max
13.53
Q3
6.54
GMAB
5.13
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Genmab (GMAB): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bio-Rad Laboratories (BIO.B) and Genmab (GMAB)
MetricBIO.BGMAB
P/E Ratio (TTM)10.3643.91
P/S Ratio (TTM)4.057.37
P/B Ratio (MRQ)1.385.13
Free Cash Flow Yield (TTM)2.59%2.70%